Trial Profile
Phase II Trial of Velcade Plus Vorinostat in the Treatment of High Risk MDS and Relapsed/Refractory AML
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Vorinostat (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 05 Jun 2012 Actual patient number is 16 according to ClinicalTrials.gov.
- 05 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Oct 2011 Planned End Date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.